Search

You searched for "practice"

477 results found

ICS updates on continence care: making sense of detrusor underactivity and the underactive bladder

1 July 2016 | | Functional Urology
Countless epidemiological studies have established the frequent occurrence of lower urinary tract symptoms (LUTS) and the significant burden these symptoms incur. For the most part of the past three decades, there has been an overwhelming focus on detrusor overactivity (DO)...

Demanding cases or nightmares in uro-oncology? Jan/Feb 2023

6 January 2023 | | Urologic Oncology
Radical surgical treatment of prostate cancer has become minimally invasive owing to robotic assisted laparoscopic technology [1]. Patients who undergo robotic assisted radical prostatectomy (RARP) often have lower risk of morbidity compared to an open approach. However, patients with a...

Nocturia – the Cinderella of lower urinary tract symptoms

1 March 2014 | | Functional Urology
Nocturia is defined as waking during the night (at least once) to urinate. The important part of the definition relates to the necessity of sleep to precede the episode (although whether sleep must follow the episode is less clear). The...

How the COVID pandemic has shaped ongoing service delivery at ERIC, The Children’s Bowel & Bladder Charity

6 January 2023 | COVID-19 - Urology News
- CHARITY FOCUS - Like many organisations and charities, COVID-19 generated a rapid period of adaptation and diversification for ERIC, The Children’s Bowel and Bladder Charity. Their Head of Communications, Alina Lynden, explains what this meant for the organisation and...

Small renal masses – diagnosis and management

1 January 2017 | | Urologic Oncology
Renal cancer is the eighth most common cancer in the UK and accounts for about 3% of all new cancer diagnoses [1]. The incidence rates are steadily rising, with the highest rates being in older men and women. This rise...

Challenges of upper tract urothelial carcinoma

1 July 2022 | | Urologic Oncology
Upper tract uroepithelial carcinoma (UTUC) is a fairly common disease which traditionally had poorer outcomes compared to bladder cancer. This is due to various factors leading to delayed diagnosis and problems in risk stratification. Continuing efforts have focused on early...

Medical statistics for urologists: part 2 – probability and hypothesis testing

2 March 2022 |
Following on from Part 1 of this series (Part 3 available here), this article aims to build on other analytical techniques commonly used within medical research, focusing on simple examples. Probability and testing Before exploring hypothesis testing, it is vital...

Post-prostatectomy incontinence

4 May 2020 | | Functional Urology, Urologic Oncology
Urinary incontinence following prostate surgery (post-prostatectomy incontinence or PPI) is a significant complication that can have a profoundly negative impact on the quality of life of patients suffering with it. It may become a barrier to physical activity and social...

Thermal ablative techniques for small renal masses

1 July 2017 | | Technological Developments, Urologic Oncology
The incidence of renal cell carcinoma has increased over the past decade which can be partly attributed to the increased use of imaging modalities [1,2]. Nephron sparing procedures for the management of small renal tumours have gained popularity which include...

Recent developments in bladder cancer

1 September 2018 | | Urologic Oncology
There have been some exciting developments in bladder cancer over the last few years. Immunotherapy has prolonged survival in a proportion of patients with metastatic disease, with sustained efficacy in some. Advances in genetic analysis and molecular subtyping make personalised...

Urinary biomarkers for surveillance of non-muscle invasive bladder cancer

1 May 2019 | | Basic Science Research, Urologic Oncology
Bladder cancer (BC) is the ninth most common cancer worldwide with a yearly incidence of approximately 430,000 cases. There is a male predominance and it is the seventh most common cancer in men worldwide [1]. Non-muscle invasive bladder cancer (NMIBC)...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | Basic Science Research, Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...